Chemotherapy Approach for Patients in Early Palliative Care

First-Line Chemotherapy Selection in Palliative Setting

The National Comprehensive Cancer Network recommends single-agent chemotherapy for patients in early palliative care to minimize toxicity while providing symptom control 2, 3
For non-small cell lung cancer patients with poor performance status or elderly patients, single-agent chemotherapy with gemcitabine, vinorelbine, or taxanes is an appropriate option 1, 4
The choice of agent should be based on prior treatment response, time since last treatment, and patient-specific factors including organ function 2, 6

For most patients in palliative care settings, limiting treatment to 2-4 cycles of single-agent chemotherapy is recommended to balance potential benefit with quality of life 1, 6

Single-agent chemotherapy with pemetrexed for non-squamous histology or gemcitabine/vinorelbine for any histology is appropriate 1, 4
For patients with poor performance status, single-agent chemotherapy is particularly important to minimize toxicity while providing symptom control 1

For relapsed small cell lung cancer in the palliative setting, single-agent topotecan, paclitaxel, docetaxel, irinotecan, or temozolomide may be considered 2, 5
Response to treatment is highly dependent on time from initial therapy to relapse, with better responses if more than 3 months have elapsed 2, 6

Single-agent chemotherapy is preferred over combination therapy in the palliative setting 7

Single-agent fluoropyrimidine should be considered for elderly patients in palliative care 8

Avoid full-dose regimens in elderly or frail patients; consider dose modifications 3, 6

Continue treatment until disease progression, unacceptable toxicity, or completion of planned cycles (typically 2-4 cycles in palliative setting) 2, 3
Regularly reassess goals of care and performance status to determine when to transition from chemotherapy to best supportive care only 6